Charles River Laboratories Intl. Inc vs Johnson Controls International PLC — how do they compare? Charles River Laboratories Intl. Inc trades at $227.4 (market cap $11.14B), while Johnson Controls International PLC trades at $141.87 (market cap $88.61B). The key difference: Johnson Controls International PLC is far larger — about 8× Charles River Laboratories Intl. Inc's market cap, and Johnson Controls International PLC pays a 1.1% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | JCI | |
|---|---|---|
Market Cap | $11.14B | $88.61B |
Sector | Health | Industrials |
52-Week High | $233.60 | $148.21 |
52-Week Low | $145.57 | $103.24 |
Enterprise Value | $14.00B | $97.44B |
Dividend Yield | — | 1.1% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Johnson Controls International (JCI) trades at $143.93, up 0.78% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS expected at $1.33. Revenue for 2025 reached $23.60 billion, with net income surging to $3.29 billion, reflecting a robust profit margin of 13.94%. Recent corporate actions include a $0.40 dividend payment scheduled for July 2026, and positive news flow highlights growth in smart home and building efficiency markets.
JCI presents a favorable investment case driven by earnings momentum, solid profitability, and a unanimous analyst buy consensus with a $158.29 price target. Key risks include elevated valuation multiples (P/E of 43.67) and rising debt-to-asset ratios, which could pressure returns if growth slows. The stock's proximity to its 52-week high suggests limited near-term upside, but operational execution and sector tailwinds support a constructive outlook for patient investors.
Trailing returns across standard periods
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →